News - Lundbeck

Filter

Current filters:

Lundbeck

Popular Filters

10 to 34 of 92 results

Lundbeck’s Brintellex available in US pharmacies for depression

Lundbeck’s Brintellex available in US pharmacies for depression

22-01-2014

Lundbeck (LUN: CO) and Takeda Pharmaceutical (TYO: 4502) jointly announced today that Brintellix (vortioxetine)…

BrintellixLundbeckMarkets & MarketingNeurologicalPharmaceuticalRegulationTakeda PharmaceuticalsUSA

Ossianix in CNS research deal with Lundbeck

Ossianix in CNS research deal with Lundbeck

07-01-2014

Privately-held US firm Ossianix has announced a strategic research collaboration with Danish central…

LundbeckNeurologicalOssianixPharmaceuticalResearch

New schizophrenia drug Abilify to lead the market by 2016

New schizophrenia drug Abilify to lead the market by 2016

29-12-2013

Long-acting depot therapy Abilify Maintena (aripiprazole) will become the leading injectable schizophrenia…

AbilifyAbilify MaintenaFinancialGlobalLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceutical

Lundbeck’s Brintellix OKed in Europe for adults with depression

Lundbeck’s Brintellix OKed in Europe for adults with depression

29-12-2013

The European Commission has granted marketing authorization for Danish CNS specialist Lundbeck’s Brintellix…

BrintellixLundbeckNeurologicalPharmaceuticalRegulation

Lundbeck appoints Jacob Tolstrup as senior vice president for Business Development

Lundbeck appoints Jacob Tolstrup as senior vice president for Business Development

16-12-2013

Danish pharmaceutical company H. Lundbeck A/S has appointed Jacob Tolstrup as head of the HR department…

BoardroomDenmarkEuropeH. LundbeckLundbeckNeurologicalPharmaceutical

Lundbeck and Otsuka to co-develop Alzheimer’s vaccine, Lu AF20513

Lundbeck and Otsuka to co-develop Alzheimer’s vaccine, Lu AF20513

11-12-2013

Danish CNS specialist Lundbeck and Japanese drugmaker Otsuka Pharmaceutical say they will further expand…

LicensingLu AF20513LundbeckNeurologicalOtsukaPharmaceuticalResearch

Lundbeck’s Brintellix scores well in new cognitive performance study

Lundbeck’s Brintellix scores well in new cognitive performance study

11-12-2013

Danish CNS specialist Lundbeck has released results from FOCUS, a new study showing that Brintellix (vortioxetine)…

BrintellixLundbeckNeurologicalPharmaceuticalResearch

FDA warns of serious skin reactions with the anti-seizure drug Onfi

FDA warns of serious skin reactions with the anti-seizure drug Onfi

04-12-2013

The US Food and Drug Administration is warning the public that the anti-seizure drug Onfi (clobazam)…

LundbeckNeurologicalNorth AmericaOnfiPharmaceuticalRegulation

Otsuka and Lundbeck’s schizophrenia drug Abilify Maintena approved in EU

Otsuka and Lundbeck’s schizophrenia drug Abilify Maintena approved in EU

21-11-2013

Japan’s Otsuka Pharmaceutical (TYO: 4768) and partner Lundbeck (LUN: CO) have received approval from…

Abilify MaintenaAsia-PacificEuropeLundbeckNeurologicalOtsukaPharmaceuticalRegulation

Lundbeck shows strong growth on lead products despite generic competition

Lundbeck shows strong growth on lead products despite generic competition

06-11-2013

Danish CNS drug specialist Lundbeck has reported revenues of 11.67 billion Danish kroner ($2.11 billion)…

FinancialLundbeckNeurologicalPharmaceutical

Lundbeck and Otsuka partner on Biotie’s nalmefene in Japan

Lundbeck and Otsuka partner on Biotie’s nalmefene in Japan

31-10-2013

Biotie Therapies says that its partner, Lundbeck has expanded its existing alliance with Otsuka Pharmaceutical…

Asia-PacificBiotechnologyBiotie TherapiesLicensingLundbeckMarkets & MarketingnalmefeneNeurologicalSelincro

New US indication for Lundbeck’s Sabril

New US indication for Lundbeck’s Sabril

29-10-2013

Danish CNS drug specialist Lundbeck says that the US Food and Drug Administration has approved its Sabril…

LundbeckNeurologicalNorth AmericaPharmaceuticalRegulationSabril

Positive EMA/CHMP opinions for Actelion and Lundbeck

Positive EMA/CHMP opinions for Actelion and Lundbeck

27-10-2013

At its October month-end meeting, the European Medicines Agency’s Committee for Medicinal Products…

ActelionBiotechnologyBrintellixEuropeLundbeckNeurologicalOpsumitPharmaceuticalRegulationRespiratory and Pulmonary

Lundbeck and Otsuka progress new add-on treatment for Alzheimer's

Lundbeck and Otsuka progress new add-on treatment for Alzheimer's

10-10-2013

Denmark-based CNS specialist Lundbeck and partner Japan’s Otsuka Pharmaceutical have announced the…

Lu AE58054LundbeckNeurologicalOtsukaPharmaceuticalResearch

Upsher-Smith in research link with Lundbeck

02-10-2013

US drugmaker Upsher-Smith Laboratories has entered into a preclinical development agreement with Denmark-based…

LundbeckNeurologicalPharmaceuticalResearchUpsher-Smith

US FDA approves new drug Brintellix to treat major depressive disorder

US FDA approves new drug Brintellix to treat major depressive disorder

01-10-2013

The US Food and Drug Administration approved Brintellix on Monday, co-marketed by Takeda and Lundbeck…

BrintellixLundbeckNeurologicalNorth AmericaPharmaceuticalRegulationTakeda Pharmaceuticals

Lundbeck continues restructuring to drive profitability

Lundbeck continues restructuring to drive profitability

01-10-2013

Lundbeck today announced the continuation of the process of evolving its business model including optimization…

EuropeFinancialLundbeckManagementPharmaceutical

Lundbeck launches Selincro in Italy

Lundbeck launches Selincro in Italy

26-09-2013

Danish CNS drug specialist Lundbeck has brought Selincro on the market in Italy.

Biotie TherapiesItalyLundbeckMarkets & MarketingNeurologicalPharmaceuticalSelincro

Biotie completes planned portfolio review

Biotie completes planned portfolio review

24-09-2013

Biotie Therapies has revealed the outcome of its planned portfolio review, following its success earlier…

Biotie TherapiesLicensingLundbeckNeurelisNeurologicalNRL-1PharmaceuticalResearchSelincrotozadenantUCB

Lundbeck files appeal over EC pay-for-delay fine

02-09-2013

Denmark-based CNS specialist drugmaker Lundbeck (LUND: CO) has filed its appeal against the European…

citalopramEuropeFinancialGenericsLegalLundbeckPharmaceutical

Sanofi latest to be implicated Chinese bribery allegations

09-08-2013

In the wake of allegations that several multinational pharma companies have engaged in unlawful marketing…

Asia-PacificLegalLundbeckMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Strong first-half underlying results from Lundbeck hit by EC fine

07-08-2013

Danish CNS specialist Lundbeck (LUN: CO) this morning (August 7) reported pleasing first-half 2013 financial…

FinancialLundbeckPharmaceutical

10 to 34 of 92 results

Back to top